Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome is a research paper published in Molecular Therapy (2024). On theSindex it has a DataRank of 0.508. It has been cited 14 times, with 11 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.406
From this paper's citation signal
Citation Network Contribution
0.102
From 8 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 11 citers.
National Research Foundation of Korea
Grant: 2021R1C1C1005725
National Institutes of Health
Grant: AWD0009884-GR120668
National Institutes of Health
Grant: MS152
National Institutes of Health
Grant: 1S10OD028504
National Institutes of Health
Grant: 1S10OD025132
NIA NIH HHS
Grant: R01 AG084184
NIH HHS
Grant: S10 OD025132
NICHD NIH HHS
Grant: R01 HD088626
NICHD NIH HHS
Grant: R21 HD077197
NCATS NIH HHS
Grant: UL1 TR001863
NICHD NIH HHS
Grant: R01 HD088007
NIMH NIH HHS
Grant: R01 MH117289
NIH HHS
Grant: S10 OD028504
NCI NIH HHS
Grant: T32 CA078207
Foundation for Prader-Willi Research
Celgene
FWCI
5.43
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords